Loading page
Loading page
Loading substance route
DOB has a notably delayed onset, typically taking 1-2 hours before effects are fully apparent. Redosing before the onset is complete significantly increases overdose risk. Stimulation and insomnia may persist well beyond the primary psychedelic experience, occasionally extending up to 36 hours at higher doses.
Effects vary widely by individual, dose, and context.
The physical effects of DOB can be broken down into five components all of which progressively intensify proportional to dosage.
The head space of DOB is described by many as one of mental stimulation and a powerful enhancement of a person's current mental state. Many users report that it may not be as deep as other traditional psychedelics such as LSD or Psilocin and that it is comparatively empty in terms of its insightfulness.
DOB presents a full and complete array of possible visual distortions.
DOB presents a full and complete array of possible visual enhancements.
The visual geometry that is present throughout this trip can be described as more similar in appearance to that of LSD, 25I-NBOMe or 2C-B than that of Ayahuasca, Psilocin or 2C-E. They can be comprehensively described as unstructured in their organization, algorithmic in geometric style, intricate in complexity, small in size, fast and smooth in motion, colourful in scheme, glossy in colour, sharp in their edges and equally rounded and angular in their corners. They give off a synthetic feel to them that at higher dosages are significantly more likely to result in states of Level 7A visual geometry over Level 7B.
DOB is capable of producing a full range of low and high level hallucinatory states in a fashion that is significantly less consistent and reproducible than that of many other commonly used psychedelics.
The auditory effects of DOB are common in their occurrence and exhibit a full range of effects.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
DOB is not habit-forming and the desire to use it typically decreases with use. It is most often self-regulating, with many users experiencing a naturally limiting quality to the substance.
DOB is not physically addictive and does not produce physical dependence or withdrawal symptoms.
Human fatalities have been reported at doses around 35 mg, while a 75 mg overdose in an individual with tolerance resulted in severe vasospasm requiring bilateral above-the-knee amputations. One fatality involved a woman who intranasally administered a large quantity believing it was MDA, with over 9 mg recovered from her tissues post-mortem. The lethal dose in humans appears to be much closer to that observed in primates than in rodents.
| Species | Route | Value |
|---|---|---|
| mouse | IV | 80 mg/kg |
| mouse | IP | 100 mg/kg |
| rat | IP | 50 mg/kg |
| monkey | IV | 2 mg/kg |
Severe vasoconstriction is the primary toxicity concern, developing progressively and peaking several hours into intoxication; at overdose levels this has resulted in diffuse arterial spasm, peripheral vasospasm, and in extreme cases gangrene requiring amputation of extremities.
Overdose can produce convulsions and seizure activity, typically occurring alongside other severe symptoms such as coma, metabolic acidosis, and cerebral edema; at typical recreational doses, the primary concerns are confusion, attention lapses, and sleep disturbances.
The long duration and stimulating nature of DOB increase the risk of psychological disturbance. Use can trigger latent psychoses, and frequent use carries risk of loss of reality that may manifest as anxiety states or schizophrenic traits. As sleep deprivation accumulates during extended experiences, stimulant psychosis may emerge with external hallucinations blending into psychedelic visuals around the 16-24 hour mark. Overdose can produce bizarre, delusional, and sometimes violent behavior.
Seizures are primarily a concern at overdose levels rather than at typical recreational doses. Convulsive activity has been documented in multiple overdose case reports, sometimes contributing to fatal outcomes. The seizure threshold may be lowered when combined with other substances such as tramadol.
DOB was first synthesized by Alexander Shulgin in 1967 as part of research examining how 4-position substitutions affect metabolic stability in phenethylamine compounds. The first published scientific report appeared in 1971, documenting toxicology findings and initial pharmacological observations.…
UN Convention on Psychotropic Substances 1971 (Schedule I)
Listed as a Schedule II controlled substance under Australian drug legislation.
Controlled under Schedule I of the Controlled Drugs and Substances Act due to its status as an amphetamine analogue.
Classified as a Schedule I controlled substance under Latvian drug control legislation.
Controlled as a Schedule I (Class A) substance. Additionally qualifies as an analogue under the catch-all provisions in Schedule 3 (Class C) of New Zealand's drug laws.
Classified as a controlled substance and designated as a high-risk drug under Romanian law.
Controlled as a Class A, Schedule 1 substance under the Misuse of Drugs Act 1971. Selling, buying, or possessing without a license is illegal.
Prohibited under the Suchtmittelgesetz (SMG). Possession, production, and sale are illegal without authorization.
Listed in Anlage I of the Betäubungsmittelgesetz since September 1, 1984. Manufacturing, possession, import, export, purchase, sale, and dispensing are prohibited without a license.
Classified as a Lijst 1 substance under the Opium Act, categorizing it as a hard drug. Production, distribution, and possession are prohibited.
Listed as a controlled substance under Polish drug legislation. Possession, production, and distribution are prohibited.
Specifically named as a controlled substance under Verzeichnis D of Swiss narcotics legislation.
Classified as a Schedule I hallucinogen under the Controlled Substances Act. Manufacturing, purchasing, possessing, or distributing without a DEA license is illegal.
16 sources cited
